Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey

Basit Öğe Kaydı
dc.authoridOzgur, Gokhan/0000-0003-0357-0503
dc.authoridKis, Cem/0000-0001-7423-7180
dc.authoridSoyer, Nur/0000-0002-7722-506X
dc.authoridGuvenc, Birol/0000-0001-7641-5673
dc.authoridHaznedaroglu, Ibrahim C./0000-0001-8028-9462
dc.authoridyilmaz, fergun/0000-0001-5118-6894
dc.authoridDurusoy, Raika/0000-0003-1041-8462
dc.contributor.authorSoyer, Nur
dc.contributor.authorAli, Ridvan
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorHaznedaroglu, Ibrahim C.
dc.contributor.authorYilmaz, Fergun
dc.contributor.authorAydogdu, Ismet
dc.contributor.authorPir, Ali
dc.date.accessioned2024-09-18T20:33:02Z
dc.date.available2024-09-18T20:33:02Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.en_US
dc.identifier.doi10.3906/sag-1812-70
dc.identifier.endpage1042en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue3en_US
dc.identifier.pmid33315343en_US
dc.identifier.scopus2-s2.0-85109571239en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1033en_US
dc.identifier.trdizinid482288en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1812-70
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/482288
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11277
dc.identifier.volume51en_US
dc.identifier.wosWOS:000668244900016en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMyelofibrosisen_US
dc.subjecttreatmenten_US
dc.subjectsurvivalen_US
dc.subjectruxolitiniben_US
dc.subjectadverse eventsen_US
dc.titleEfficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
357.04 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu